Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.
Actively Recruiting
Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.
Actively Recruiting
This research aims to evaluate the effectiveness of AZD5335 compared to standard treatments in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study focuses on whether AZD5335 improves progression-free survival PFS among participants with either high or low levels of folate receptor alpha FR. Approximately 1100 adult women will be enrolled and divided into two groups based on their FR levels. Participants will be randomized within each group to receive either AZD5335 or the relevant standard treatment. Those with high FR levels will receive AZD5335 or mirvetuximab soravtansine, while those with low FR levels will receive AZD5335 or a chemotherapy agent chosen by the investigator, including paclitaxel, pegylated liposomal doxorubicin, or topotecan. Treatments are given intravenously, and participants will continue treatment until disease progression or other reasons for stopping. During the study, participants will undergo regular tumor assessments to monitor disease status. Researchers will follow all participants over time to evaluate overall survival. Safety and efficacy data will be reviewed periodically by an independent committee. The primary outcome is progression-free survival, measured for up to about five years. The study completion is expected by late 2029.
Actively Recruiting
Chronic leg and foot ulcers are wounds that do not heal properly over 4 to 8 weeks despite standard care, often due to vascular problems like chronic venous insufficiency and peripheral artery disease. These conditions reduce blood flow, limiting oxygen and nutrients needed for healing, and cause ongoing inflammation and infection. This trial evaluates a new combined optical and magnetic stimulation COMS therapy alongside standard care to improve healing, pain, quality of life, and economic outcomes for patients with venous leg ulcers, including those with arterial complications. Participants will be randomly assigned to receive either standard care alone or standard care plus COMS therapy. Standard care includes wound cleaning, dressing changes, debridement, analgesics as needed, and compression therapy according to guidelines. The COMS treatment is applied 2 to 3 times per week for at least 8 weeks using a specialized device during standard care procedures. If patients receive care at home, trained caregivers will perform these treatments. During the 24-week study, participants will have regular assessments to monitor wound healing, pain, quality of life, and ulcer recurrence. Researchers will measure the percent reduction in wound area as the primary outcome after 24 weeks, along with complete wound closure and time to healing. Safety and device usability will also be evaluated. The study is single-blinded with data assessors unaware of group assignments and includes multiple clinical sites across several countries.
Actively Recruiting
Researchers are evaluating the effect of continued nutritional support after hospital discharge compared to usual care in medical patients at nutritional risk. This trial focuses on adults who have experienced malnutrition, a condition linked to higher risks of death, rehospitalization, and loss of function, especially among elderly and multi-ill patients. Previous studies showed that in-hospital nutritional support helps reduce complications and mortality, but the long-term benefits after discharge remain unclear. Participants are randomly assigned to one of two groups. The intervention group receives customized nutritional support from an experienced dietician to meet their individual energy and protein needs, including oral nutritional supplements as needed. The control group receives general advice on healthy eating habits at discharge without ongoing nutritional support. Follow-up includes regular phone calls every 2 to 4 weeks to monitor adherence and adjust dietary plans as necessary. During the study, participants are monitored for up to three years. Researchers assess key outcomes such as time to death from any cause, hospital readmissions, major complications, and changes in functional status using the Barthel index. Quality of life is measured with the European Quality of Life 5 Dimensions index and a visual-analogue scale at regular intervals by phone. This comprehensive follow-up helps determine whether sustained nutritional support after discharge improves long-term health and recovery.
Actively Recruiting
Researchers are evaluating a new treatment approach for patients with advanced non-small cell lung cancer NSCLC who have experienced disease progression after chemoimmunotherapy. This Phase II trial studies the combination of gemcitabine, a chemotherapy drug known for its immunostimulatory effects, with ivonescimab, a bispecific antibody targeting PD-1 and VEGF pathways. The study aims to assess if this combination can improve tumor response using RECIST v1.1 criteria, addressing the limited options available after standard treatments fail. Participants will receive gemcitabine according to standard protocols, combined with ivonescimab administered at 20 mgkg every three weeks. Ivonescimab works by targeting immune checkpoints and tumor blood vessel growth, potentially enhancing the immune systems attack on cancer. The trial is single-arm and open-label, meaning all participants receive the combination treatment, and the research team monitors responses over time. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests to monitor blood counts and organ function, and evaluations of side effects. The main outcome is the objective response rate at the end of treatment, with follow-up measuring duration of response and progression-free survival for up to two years. The study ensures diverse participant inclusion and tracks safety throughout the treatment and observation periods.
Actively Recruiting
Researchers are evaluating treatment options for patients aged 70 and older with metastatic non-small cell lung cancer NSCLC who have lower than 50% PD-L1 expression and may be frail or in poor health. The study aims to compare the safety and effectiveness of reduced-dose chemotherapy combined with cemiplimab versus cemiplimab alone. This research addresses a gap in evidence for older and frail patients who often cannot tolerate standard chemotherapy doses well. Participants are randomly assigned to one of two groups one receives reduced-dose platinum-doublet chemotherapy combined with cemiplimab, while the other receives cemiplimab monotherapy. The chemotherapy regimens differ according to cancer histology and are given intravenously every three weeks for four cycles, followed by maintenance cemiplimab treatment for up to two years. Patients whose cancer progresses may switch from monotherapy to the combination treatment if suitable. Throughout the study, participants undergo regular imaging scans to assess tumor response every 6 to 12 weeks, along with quality-of-life questionnaires and geriatric assessments of physical function at set intervals. Researchers will monitor progression-free survival, overall survival, response rates, side effects, and overall treatment utility. The trial includes ongoing safety monitoring and aims to provide evidence to improve treatment strategies for older, vulnerable NSCLC patients.
Actively Recruiting
Researchers are evaluating the efficacy and safety of an adjuvant treatment combining sacituzumab tirumotecan with pembrolizumab compared to treatment chosen by physicians in people with triple-negative breast cancer TNBC who received neoadjuvant therapy but did not achieve a complete response at surgery. This Phase 3, randomized, open-label study aims to determine if the combination improves invasive disease-free survival compared to pembrolizumab alone or pembrolizumab combined with capecitabine. Participants are randomly assigned to one of two groups. One group receives pembrolizumab every 6 weeks along with sacituzumab tirumotecan every 2 weeks for a total of 24 weeks, with premedication including antihistamines, H2 antagonists, acetaminophen, and dexamethasone before sacituzumab tirumotecan infusions. The other group receives pembrolizumab every 6 weeks alone or combined with capecitabine taken orally twice daily on specific days over 24 weeks. The study treatments are given intravenously or by mouth according to schedule. During the study, participants undergo regular assessments to monitor disease status, quality of life, and adverse events. Researchers measure invasive disease-free survival for up to approximately 77 months, along with overall survival and distant recurrence-free survival for up to about 101 months. Quality of life is evaluated using standardized questionnaires at baseline and periodically for up to 60 months. Safety is closely monitored, including recording adverse events and treatment discontinuations. The total study duration may last over a decade, with long-term follow-up to assess outcomes and treatment effects.
Actively Recruiting
Researchers are studying whether weekly acupuncture sessions over eight weeks can help reduce psychological distress in breast cancer patients who have recently finished their main treatments. This trial focuses on women transitioning into survivorship, a vulnerable period marked by increased stress, fear of cancer returning, and feelings of isolation. The study compares acupuncture with standard care, aiming to see if acupuncture lowers stress and improves quality of life and other mental health factors. Participants are randomly assigned to receive either eight weekly acupuncture sessions or standard supportive care, which may include psychosocial support or support groups. Those in the control group will have access to acupuncture after completing the initial assessment period. The acupuncture involves both body and ear treatments delivered once a week during the intervention. During the study, participants will undergo assessments of distress, quality of life, anxiety, depression, resilience, fatigue, cognitive function, therapy adherence, and any adverse events. Distress levels are measured before and after each acupuncture session, with primary outcomes evaluated after the eight-week intervention. The study will monitor these effects to understand the potential benefits and impacts of acupuncture during breast cancer survivorship.
Actively Recruiting
Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines. Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies. During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.
1-10 of 11
1